Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions

The European research collaboration for Children's Interstitial Lung Disease (ChILDEU) ERS Clinical Research Collaboration

Steve Cunningham, Carlee Gilbert, Nico Schwerk on behalf of the ChILDEU Clinical Research Collaboration Management Committee
European Respiratory Journal 2018 52: 1801855; DOI: 10.1183/13993003.01855-2018
Steve Cunningham
1Dept of Child Life and Health, Centre for Inflammation Research, University of Edinburgh, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carlee Gilbert
2ChILD Lung Foundation, Wallasey, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nico Schwerk
3Hannover Medical School, Hannover, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

Enhanced clinical, parent, academic and industry engagement in the field of children's interstitial lung diseases will help improve case ascertainment, mechanisms and therapeutic developments for these ultra-rare conditions http://ow.ly/SM0I30mC3Jk

Rationale

There are over 200 conditions collectively assigned as children's interstitial (or diffuse) lung disease (ChILD), with a prevalence of 1.5 [1] to 3.6 [2] per million children per year. The conditions individually are rare to ultra-rare and are lumped for convenience [3], but studies need larger cohorts for each condition, in order to deliver progress. As most university hospitals see between one and five new ChILD cases each year [4], progress is slow unless international co-operation is in place.

The development of ChILD networks has seen several national database initiatives, including the chILD Foundation in the USA [5] (initiated by Robin Deterding), RespiRare in France [6] (coordinated by Annick Clement) and the Kids Lung Register (www.kids-lung-register.eu) in Germany (organised by Matthias Griese), together with databases in the UK [7] and Australia [1]. The organic development of these initiatives at national level, whilst beneficial, increasingly makes us aware of the limitations of national datasets for the future expansion of ChILD knowledge. In 2013, for the first time, a European Union (EU) 7th Framework Programme (FP7)-funded project developed an international registry, database and biobank: the chILD-EU project (www.childeu.net). The project systematically collated cases of ChILD, provided international peer review, and supported biobanking of radiology, pathology and laboratory samples (including DNA) [8]. In addition, anecdotal use of treatments was reassessed via a Delphi process to provide recommendations for management [8], and patient-reported outcomes were derived [9]. chILD-EU initiatives are bearing fruit, with the publication of larger retrospective series of more frequently occurring ChILD conditions [10, 11].

The European Respiratory Society (ERS) call to develop a Clinical Research Collaboration (CRC) [12] was a timely springboard for ChILD, coming toward the end of the EU FP7 funding. The European research collaboration for Children's Interstitial Lung Disease (ChILDEU) CRC commenced in April 2016 within the Paediatric Assembly of the ERS.

Aims

ChILDEU CRC funding enabled us to maintain the momentum created by the FP7 project, but also to consider how best to enhance future opportunities. There were four key aims for ChILDEU: 1) to derive a common international minimum dataset with agreed field terms and descriptors; 2) to enable a wider range of clinicians to recognise, diagnose, manage and support ChILD conditions; 3) to create an international parent/patient partnership to encourage support for ChILD at a local, national and international level; and 4) to encourage and support engagement and investment by academia and industry for ChILD.

Past achievements

The ChILDEU CRC, recognising the rarity of ChILD conditions and the regulatory and mindset hurdles to the development of a truly global database, has worked to devise a common minimum dataset. At a CRC meeting in Prague in 2017, representatives of the global ChILD database agreed in principle to deliver a commonly preserved minimum dataset with descriptions and fields that are changed only by common international agreement. For the ChILDEU CRC this is continuing work with international and industry collaborators, and progress is being made.

The CRC now delivers free, succinct and accessible educational opportunities for ChILD through webinars. The objectives are to improve diagnosis and management of ChILD [13] within Europe, and also as a global resource [14]. Access is open to all, but with a particular focus on early career trainees. The webinars, hosted by a University of Edinburgh (Edinburgh, UK) platform, are 1 h in duration with a presentation by an expert in ChILD, and Continuing Professional Development certificates of attendance are provided to attendees. Recordings of the webinars are available at www.klinikum.uni-muenchen.de/Child-EU/en/crc/webinar-series/index.html.

The ChILDEU CRC has a key aim to develop a greater international reach for parents and children affected by ChILD. Working with the European Lung Foundation (ELF), we have developed an international parent and patient group. The ELF has been instrumental in enabling communication across time zones and providing support in multiple languages. The group have developed, delivered and analysed a survey of patient and parent perspectives of ChILD, informed by 156 participants from 15 countries, with results presented at the ERS International Congress in Paris (France) in September 2018. The group have also, in liaison with the ELF and ChILDEU CRC, developed a ChILD website, containing key information and practical help on the management of ChILD conditions (www.europeanlunginfo.org/child/).

Delivering clinical trials in ChILD presents enormous challenges from both logistic and scientific perspectives: the chILD-EU FP7 randomised controlled trial of hydroxychloroquine in interstitial lung disease (the first randomised controlled trial in ChILD) has been beset by regulatory challenges [13]. Trials of therapeutics to treat individual diseases and resulting pathology (i.e. fibrosis) are in pre-clinical development for ChILD. To support research infrastructure for future trials, the ChILDEU CRC is working to identify clinical outcomes for ChILD interventions. The ChILDEU Register now includes standardised structured observational data of over 600 patients (128 incident and over 500 prevalent cases) [8], and prospective analyses are in progress.

Future plans

The future for ChILD lies with enhanced case ascertainment and a greater assimilation of knowledge of phenotypes for individual diseases and pathophysiological groups (i.e. fibrotic diseases). The ChILDEU CRC will enhance this capacity through a greater reach of educational opportunities and parental empowerment. The potential of therapeutic options for ChILD will lead to greater clinician engagement. A ChILDEU CRC Translational Science meeting will be held in Edinburgh in June 2019 with this educational aim. The ChILDEU CRC will collaborate with other CRC groups, particularly to explore understanding of genomics through studies of lung expression in paediatric and adult interstitial lung disease (in the ERS Lung Fibrosis Clinical Research Group). The work of parent groups (in liaison with the ELF) has been a highlight so far within the CRC, helping to identify key areas for clinical focus, as described. We will build on these to help deliver a better patient experience across EU countries and language barriers.

Challenges

Whilst the ChILD common minimum dataset is agreed in principle across the global database, initiatives that are running in parallel but at a different pace (i.e. the European Reference Network for rare respiratory diseases (ERN-LUNG) database, and pharma initiatives) may cause traction, but do not deflect from the ultimate value of this aim. Rare lung disease in children remains extremely vulnerable to the pressures of competing diseases, particularly in countries with limited resources. The ChILDEU CRC will continue to develop international promotion of ChILD through support of local clinicians and parent groups. Some ChILD genetic conditions could be adaptable to intervention, and enhanced case ascertainment will enable us to develop greater academic and industry engagement. The ChILDEU CRC continues to search for strategies to facilitate genetic testing of children at low cost where there is a high probability of a genetically associated ChILD (i.e. surfactant deficiencies, COPA syndrome (mutations in the COPA gene), SAVI (STING-associated vasculopathy with onset in infancy), etc.), regardless of geography.

Acknowledgments

For more information on the ChILDEU Clinical Research Collaboration, including how to contribute, contact ChILDEUCRC{at}ed.ac.uk or see the information for clinicians at www.childeu.net. The European Lung Foundation website at www.europeanlunginfo.org/child gives further information for parents/patients.

Footnotes

  • Members of the ChILDEU Clinical Research Collaboration Management Committee: Steve Cunningham (Chair), Nico Schwerk (Chair), Carlee Gilbert (patient representative), Andy Bush, Annick Clement, Robin Deterding, Matthias Griese, Adam Jaffe, Fabio Midulla, Deborah Snyder and Jeanette Boyd (European Lung Foundation representative).

  • Conflict of interest: S. Cunningham reports fees from Boehringer Ingelheim, paid to Edinburgh University for consultancy work, outside the submitted work.

  • Conflict of interest: C. Gilbert has nothing to disclose.

  • Conflict of interest: N. Schwerk has nothing to disclose.

  • Support statement: Funding was received from the European Respiratory Society, grant ERS CRC2015-02 (ChILDEU). Funding information for this article has been deposited with the Crossref Funder Registry.

  • Received September 29, 2018.
  • Accepted November 1, 2018.
  • Copyright ©ERS 2018

References

  1. ↵
    1. Saddi V,
    2. Beggs S,
    3. Bennetts B, et al.
    Childhood interstitial lung diseases in immunocompetent children in Australia and New Zealand: a decade's experience. Orphanet J Rare Dis 2017; 12: 133.
    OpenUrl
  2. ↵
    1. Dinwiddie R,
    2. Sharief N,
    3. Crawford O
    . Idiopathic interstitial pneumonitis in children: a national survey in the United Kingdom and Ireland. Pediatr Pulmonol 2002; 34: 23–29.
    OpenUrlCrossRefPubMedWeb of Science
  3. ↵
    1. Nicholson AG,
    2. Bush A
    . Classification of diffuse lung disease in infants: the reality of groups. Am J Respir Crit Care Med 2007; 176: 1060–1061.
    OpenUrlCrossRefPubMedWeb of Science
  4. ↵
    1. Hime NJ,
    2. Zurynski Y,
    3. Fitzgerald D, et al.
    Childhood interstitial lung disease: a systematic review. Pediatr Pulmonol 2015; 50: 1383–1392.
    OpenUrlCrossRefPubMed
  5. ↵
    1. Deterding RR
    . Children's interstitial and diffuse lung disease. Progress and future horizons. Ann Am Thorac Soc 2015; 12: 1451–1457.
    OpenUrl
  6. ↵
    1. Nathan N,
    2. Taam RA,
    3. Epaud R, et al.
    A national internet-linked based database for pediatric interstitial lung diseases: the French network. Orphanet J Rare Dis 2012; 7: 40.
    OpenUrlCrossRefPubMed
  7. ↵
    1. Laverty A,
    2. Jaffé A,
    3. Cunningham S
    . Establishment of a web-based registry for rare (orphan) pediatric lung diseases in the United Kingdom: the BPOLD registry. Pediatr Pulmonol 2008; 43: 451–456.
    OpenUrlCrossRefPubMed
  8. ↵
    1. Bush A,
    2. Cunningham S,
    3. de Blic J, et al.
    European protocols for the diagnosis and initial treatment of interstitial lung disease in children. Thorax 2015; 70: 1078–1084.
    OpenUrlAbstract/FREE Full Text
  9. ↵
    1. Niemitz M,
    2. Schwerk N,
    3. Goldbeck L, et al.
    Development and validation of a health-related quality of life questionnaire for pediatric patients with interstitial lung disease. Pediatr Pulmonol 2018; 53: 954–963.
    OpenUrl
  10. ↵
    1. Kröner C,
    2. Wittmann T,
    3. Reu S, et al.
    Lung disease caused by ABCA3 mutations. Thorax 2017; 72: 213–220.
    OpenUrlAbstract/FREE Full Text
  11. ↵
    1. Rauch D,
    2. Wetzke M,
    3. Reu S, et al.
    Persistent tachypnea of infancy. Usual and aberrant. Am J Respir Crit Care Med 2016; 193: 438–447.
    OpenUrl
  12. ↵
    1. Brightling C,
    2. Genton C,
    3. Bill W, et al.
    ERS Clinical Research Collaborations: underpinning research excellence. Eur Respir J 2018; 52: 1801534.
    OpenUrlAbstract/FREE Full Text
  13. ↵
    1. Griese M,
    2. Seidl E,
    3. Hengst M, et al.
    International management platform for children's interstitial lung disease (chILD-EU). Thorax 2018; 73: 231–239.
    OpenUrlAbstract/FREE Full Text
  14. ↵
    1. Aryan Z,
    2. Modaresi M
    . Paediatric orphan lung diseases in Asia. Lancet Respir Med 2016; 4: 174–175.
    OpenUrl
PreviousNext
Back to top
View this article with LENS
Vol 52 Issue 6 Table of Contents
European Respiratory Journal: 52 (6)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
The European research collaboration for Children's Interstitial Lung Disease (ChILDEU) ERS Clinical Research Collaboration
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
The European research collaboration for Children's Interstitial Lung Disease (ChILDEU) ERS Clinical Research Collaboration
Steve Cunningham, Carlee Gilbert, Nico Schwerk
European Respiratory Journal Dec 2018, 52 (6) 1801855; DOI: 10.1183/13993003.01855-2018

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
The European research collaboration for Children's Interstitial Lung Disease (ChILDEU) ERS Clinical Research Collaboration
Steve Cunningham, Carlee Gilbert, Nico Schwerk
European Respiratory Journal Dec 2018, 52 (6) 1801855; DOI: 10.1183/13993003.01855-2018
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Rationale
    • Aims
    • Past achievements
    • Future plans
    • Challenges
    • Acknowledgments
    • Footnotes
    • References
  • Info & Metrics
  • PDF
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Addressing the effect of ancestry on lung volume
  • Bronchodilators in bronchiectasis: there is light but it is still too dim
  • Consensus statement on quality standards for managing children with bronchiectasis
Show more Editorials

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Reviewers
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2022 by the European Respiratory Society